These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 18563891

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Altered peptide ligands of myelin basic protein ( MBP87-99 ) conjugated to reduced mannan modulate immune responses in mice.
    Katsara M, Yuriev E, Ramsland PA, Tselios T, Deraos G, Lourbopoulos A, Grigoriadis N, Matsoukas J, Apostolopoulos V.
    Immunology; 2009 Dec; 128(4):521-33. PubMed ID: 19930042
    [Abstract] [Full Text] [Related]

  • 7. Properties of myelin altered peptide ligand cyclo(87-99)(Ala91,Ala96)MBP87-99 render it a promising drug lead for immunotherapy of multiple sclerosis.
    Deraos G, Rodi M, Kalbacher H, Chatzantoni K, Karagiannis F, Synodinos L, Plotas P, Papalois A, Dimisianos N, Papathanasopoulos P, Gatos D, Tselios T, Apostolopoulos V, Mouzaki A, Matsoukas J.
    Eur J Med Chem; 2015 Aug 28; 101():13-23. PubMed ID: 26112377
    [Abstract] [Full Text] [Related]

  • 8. Design and synthesis of a potent cyclic analogue of the myelin basic protein epitope MBP72-85: importance of the Ala81 carboxyl group and of a cyclic conformation for induction of experimental allergic encephalomyelitis.
    Tselios T, Probert L, Daliani I, Matsoukas E, Troganis A, Gerothanassis IP, Mavromoustakos T, Moore GJ, Matsoukas JM.
    J Med Chem; 1999 Apr 08; 42(7):1170-7. PubMed ID: 10197961
    [Abstract] [Full Text] [Related]

  • 9. Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators.
    Matsoukas J, Apostolopoulos V, Kalbacher H, Papini AM, Tselios T, Chatzantoni K, Biagioli T, Lolli F, Deraos S, Papathanassopoulos P, Troganis A, Mantzourani E, Mavromoustakos T, Mouzaki A.
    J Med Chem; 2005 Mar 10; 48(5):1470-80. PubMed ID: 15743189
    [Abstract] [Full Text] [Related]

  • 10. A putative bioactive conformation for the altered peptide ligand of myelin basic protein and inhibitor of experimental autoimmune encephalomyelitis [Arg91, Ala96] MBP87-99.
    Mantzourani ED, Tselios TV, Grdadolnik SG, Brancale A, Platts JA, Matsoukas JM, Mavromoustakos TM.
    J Mol Graph Model; 2006 Sep 10; 25(1):17-29. PubMed ID: 16310386
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mannosylation of mutated MBP83-99 peptides diverts immune responses from Th1 to Th2.
    Katsara M, Yuriev E, Ramsland PA, Deraos G, Tselios T, Matsoukas J, Apostolopoulos V.
    Mol Immunol; 2008 Aug 10; 45(13):3661-70. PubMed ID: 18541301
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rational design and synthesis of altered peptide ligands based on human myelin oligodendrocyte glycoprotein 35-55 epitope: inhibition of chronic experimental autoimmune encephalomyelitis in mice.
    Tselios T, Aggelidakis M, Tapeinou A, Tseveleki V, Kanistras I, Gatos D, Matsoukas J.
    Molecules; 2014 Nov 04; 19(11):17968-84. PubMed ID: 25375337
    [Abstract] [Full Text] [Related]

  • 18. Design of protease-resistant myelin basic protein-derived peptides by cleavage site directed amino acid substitutions.
    Burster T, Marin-Esteban V, Boehm BO, Dunn S, Rotzschke O, Falk K, Weber E, Verhelst SH, Kalbacher H, Driessen C.
    Biochem Pharmacol; 2007 Nov 15; 74(10):1514-23. PubMed ID: 17803968
    [Abstract] [Full Text] [Related]

  • 19. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.
    Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, McFarland HF, Martin R.
    Nat Med; 2000 Oct 15; 6(10):1167-75. PubMed ID: 11017150
    [Abstract] [Full Text] [Related]

  • 20. MBP-8298, a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis.
    Darlington C.
    Curr Opin Mol Ther; 2007 Aug 15; 9(4):398-402. PubMed ID: 17694453
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.